- Podcast
- 31/01/2019
- UK
Neoadjuvant Denosumab: Its Role and Results in Operable Cases of Giant Cell Tumour of Bone
Description
In this podcast episode from The Bone & Joint Journal, host Andrew Duckworth and sub-specialty editor Sam Patton explore the critical insights of Professor Ajay Puri regarding his paper on the role of neoadjuvant denosumab in the treatment of operable giant cell tumors of the bone. The podcast opens with introductions and a brief overview of the podcast’s aim to enhance the accessibility of research findings for both readers and authors. Throughout the discussion, Professor Puri shares his medical and clinical experiences from the Tata Memorial Hospital in Mumbai, a leading oncology center in India, emphasizing the significance of denosumab as a monoclonal antibody that aids in reducing osteoclast activity in giant cell tumors.
The speakers dive into the variations of treatment available for giant cell tumors, where Professor Puri elaborates on the criteria and selection of patients who can benefit from denosumab, the financial considerations affecting treatment accessibility, and the study's findings on local recurrence rates associated with different treatment tactics. The conversation also addresses the implications of using denosumab, including its potential to facilitate safer surgical procedures by creating a dense bony rim around the tumors, thus enhancing the prospects of successful curettage while respecting the patients' desire to preserve their natural bone during their young-adult lives.
As the episode concludes, the speakers reflect on the future of denosumab in clinical practice, advocating for judicious use in surgery to balance efficacy with the limitations observed. Listeners are encouraged to engage with the subjects raised and share their thoughts across social media. Overall, this podcast serves as an insightful resource for understanding advances in orthopedic oncology and the complexities involved in treating giant cell tumors.